Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT).
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT).
复制标题
DOI：
10.1016/j.cmi.2020.12.011
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Italian Society of Infectious and Tropical Diseases
中科院分区：
文献类型：
--
作者：
Mussini C;Falcone M;Nozza S;Sagnelli C;Parrella R;Meschiari M;Petrosillo N;Mastroianni C;Cascio A;Iaria C;Galli M;Chirianni A;Sagnelli E;Iacobello C;Di Perri G;Mazzotta F;Carosi G;Tinelli M;Grossi P;Armignacco O;Portelli V;Andreoni M;Tavio M;Italian Society of Infectious and Tropical Diseases
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)感染已成为一种大流行，全世界已有近100万人死亡。目前，冠状病毒病2019年的标准治疗(新冠肺炎)没有得到很好的定义，因为来自随机或观察性研究的证据，尽管结果相互矛盾，但已导致治疗指南迅速变化。我们的目的是叙述性地总结有关新冠肺炎管理的现有文献，以便将当前的证据和在一线治疗患者的专家对数据的解释结合起来。该小组对每一种可能的治疗方法的随机临床试验的文献和最终新闻稿进行了详细的审查。对与该主题相关的出版物进行归纳性PubMed搜索，包括进行的所有临床试验。结果是一个流程图，列出了新冠肺炎患者的治疗适应症。在经历了6个月的大流行局势之后，在可能的第二波冠状病毒浪潮降临欧洲之前，重要的是评估哪些药物被证明是有效的，同时也考虑到许多随机临床试验的结果仍在等待。事实上，在已发表的随机对照试验中，在新冠肺炎的治疗中，只有糖皮质激素与显著降低死亡率有关。迫切需要新的治疗策略。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. The panel conducted a detailed review of the literature and eventual press releases from randomized clinical trials for each possible available treatment. Inductive PubMed search waws performed for publications relevant to the topic, including all clinical trials conducted. The result was a flowchart with treatment indications for patients with COVID-19. After 6 months of a pandemic situation and before a possible second coronavirus wave descends on Europe, it is important to evaluate which drugs proved to be effective while also considering that results from many randomized clinical trials are still awaited. Indeed, among treatments for COVID-19, only glucocorticoids have resulted in an association with a significant decrease in mortality in published randomized controlled trials. New therapeutic strategies are urgently needed.
登录
查看更多内容
影响因子：
82.9
作者：
Giavridis T;van der Stegen SJC;Eyquem J;Hamieh M;Piersigilli A;Sadelain M
通讯作者：
Sadelain M
DOI：
10.15557/pimr.2020.0003
发表时间：
2020-01-01
影响因子：
3.6
作者：
通讯作者：
--
影响因子：
7.6
作者：
Brown, Ariane J.;Won, John J.;Sheahan, Timothy P.
通讯作者：
Sheahan, Timothy P.
影响因子：
158.5
作者：
Cavalcanti, A. B.;Zampieri, F. G.;Berwanger, O.
通讯作者：
Berwanger, O.
影响因子：
19
作者：
Harvala, Heli;Mehew, Jennifer;Zambon, Maria
通讯作者：
Zambon, Maria